http://www.glosunspa.com ~ Houston Tanning Salon ~ Phone (713) 662-9200 Glo Sun Spa is the most luxurious spot in Houston for indoor tanning and skin care. Glo is actually a working showroom that features all the newest technology from the top manufacturers worldwide. Equipment choices include VersaSpa, Lumiere Light Therapy, Ergoline, KBL America, Tan America, Sportareddo, Dr. Mueller, Hydration Station, and Sun Italia. When you become a member at Glo Sun Spa, you can indulge in all the finest equipment available worldwide! Enjoy! Glo Sun Spa, 3273 Southwest Freeway, Houston, TX 77027, (713) 662-9200 http://www.glosunspa.com
On May 27, CVS/pharmacy launched a new in-store fundraising campaign named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS) and cystic fibrosis (CF). Funds raised through the campaign will benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis. Supporters for the 2012 campaign can donate $1 or $3 dollars at the register in CVS/pharmacy locations and online at www.cvs.com/alscff through June 30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56330-cvs-pharmacy-fundraising-campaign-support-als-and-cystic-fibrosis
http://www.trainorsportsmedicine.com
Trainor Sports Medicine - We provide a concentration in pain control, for musculoskeletal injuries, which may include injections of cortisone, viscol supplementation including for example euflexxa, hyaline, and synvisc as well as, prp (platelet rich plasma therapy).
http://www.trainorsportsmedicine.com
Trainor Sports Medicine is Dedicated To Safe Participation In Sports, we specialist in providing a concentration in pain control, for musculoskeletal injuries, which may include injections of cortisone, viscol supplementation including for example euflexxa, hyaline and synvisc as well as, prp (platelet rich plasma therapy).
‘Tis the Season for last-minute holiday shopping, and this year the rush is on. According to the National Retail Federation, more than 40 percent of people have shopping left to complete. Fortunately, shoppers can look to Wahl for those must-have, much-appreciated gifts for everyone on the list. The company’s “look good at the last minute” holiday lineup includes new, budget-friendly offerings in men’s grooming, massage therapy and pet. Plus, a new online destination, Wahlholidaygifts.com, makes looking good at the last minute easier than ever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55488-wahl-holiday-gifts-lineup-for-last-minute-shopping-wahlholidaygifts
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
They say it’s the thought that counts. However, more than half of all holiday shoppers are expected to return gifts, according to a recent national survey. Fortunately, Wahl, a leader in men’s grooming and personal care, has a holiday lineup designed with staying power. The company’s latest offerings consist of budget-friendly gifts for everyone on the list, including new lithium-ion-powered grooming tools, temperature-therapy massage solutions and odor-fighting products for pets.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64839-wahl-holiday-lineup-men-s-grooming-and-personal-care
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Rosecrance, one of the country’s leading teen substance abuse treatment centers, has launched a traveling art exhibit to help parents understand teenagers’ points of view about pressures they encounter and how they are faced with the potential to use, and abuse, substances. Developed by teen patients participating in an art therapy program at Rosecrance’s adolescent campus in Rockford, IL, “In My Shoes” encourages parents to understand their teen’s point of view and actively parent to help teens navigate today’s confusing environment.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7348551-rosecrance-s-in-my-shoes-traveling-art-exhibit-parents-teenagers-prevent-substance-abuse/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
